logo-loader
viewAdmedus Ltd

Admedus to begin first-in-human SAVR trial of single-piece 3D aortic valve this quarter

The proposal follows Professor Meuris’ confidence in the prototype aortic valve after his recent investigation of the ADAPT® single-piece 3D aortic valve replacement in sheep.

Admedus Ltd - Admedus receives approval for first-in-human surgical aortic valve replacement
Admedus is a structural heart company delivering clinically superior solutions

Admedus Ltd (ASX:AHZ) will begin the first-in-human surgical aortic valve replacement (SAVR) trial later this quarter of its proprietary ADAPT® single-piece 3D aortic valve.

This trial will take place at the Leuven University Hospitals and follows the UZ Leuven Medical Ethics Committee approving the clinical trial protocol.

The SAVR market is estimated at US$3 billion by 2023 with more than 250,000 procedures performed in Europe and North America in 2018.

Renowned surgeon for trial

Professor Bar Meuris, a renowned surgeon at the University Hospitals in Leuven, Belgium, is conducting the clinical trial sponsored by Admedus Regen Pty Ltd, a wholly-owned subsidiary of Admedus.

Fifteen patients will be enrolled in the study and will be followed up for six months after receiving implantation of the ADAPT® single-piece 3D aortic valve.

The results from the study are expected to be available between Q1 2021 and Q3 2021.

“Important next step”

Chief executive officer Wayne Paterson said: “This endorsement of our ADAPT® single-piece 3D aortic valve technology is an important next step to our development pathway.

“The ADAPT® single-piece 3D aortic valve has demonstrated excellent haemodynamics, both on the bench and in animal testing, and we expect to see that replicated in humans.

“The ADAPT® single-piece 3D aortic valve is uniquely designed as it is essentially the same valve whether it is placed surgically or by TAVR and will thus provide valuable information for the Admedus TAVR program as we move forward.

“Ultimately, we expect to see better outcomes for patients over the course of this study.”

Notable for durability

Following Professor Meuris’ recent investigation of the ADAPT® aortic valve replacement in an ovine model (sheep), he expects that the product will produce similar positive results in humans.

The company’s proprietary ADAPT® bio-scaffold material is notable for its durability and zero calcification virtues evidenced by 10 years of published and peer-reviewed data.

The ovine study was performed on six juvenile sheep, which are a preferred model for bioprosthetic valve implantation.

Key results from the study:

  • Normal valve function postoperatively after aortic valve replacement with the ADAPT® single-piece 3D aortic valve;
  • Follow-up up to six months revealed good and stable valve function;
  • The valve tissue was easy to handle during surgical implantation and might translate into the clinical setting;
  • No material failure or fatigue of the valve material was observed;
  • Echocardiography showed low gradients and no significant regurgitation across implanted valves; and
  • No contra-indication for a continuation towards a first-in-human trial with this prothesis.

Quick facts: Admedus Ltd

Price: 4.2 AUD

ASX:AHZ
Market: ASX
Market Cap: $24.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus Ltd proud to unveil its valves publicly for the first time in London

Admedus Ltd's (ASX:AHZ) CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London. The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business. Paterson says the focus is now firmly on the Adapt...

on 20/11/19

3 min read